Keros Therapeutics, Inc. (KROS) Revenue 2019–2025
Keros Therapeutics, Inc. (KROS) annual revenue history from SEC filings — each fiscal year as reported, with year-over-year change.
$244.1MFY2025 · since FY2019: $10.0M → $244.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $244.1M | +6775.0% |
| FY2024 | $3.5M | +2251.0% |
| FY2023 | $151,000 | — |
| FY2022 | $0 | -100.0% |
| FY2021 | $20.1M | — |
| FY2020 | $0 | -100.0% |
| FY2019 | $10.0M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More KROS financial trends
KROS Net incomeKROS Net marginKROS Gross profitKROS Gross marginKROS Operating incomeKROS Operating marginKROS Operating cash flowKROS Free cash flowKROS Capital expendituresKROS Return on equityKROS Stock buybacksKROS Dividends paidKROS Total assetsKROS Total liabilitiesKROS Shareholders’ equityKROS overview →